Immunostimulants drugs for COVID-19 - live meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	RCT OBS RCT + OBS	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
RECOVERY (plasma), 2021 NCT04381936		RCT	convalescent plasma treatment	control	COVID 19 hospitalized	NA	-/-	inconclusive
ACTIV-3/TICO LY-CoV555 , 2020 NCT04501978		RCT	neutralizing antibody	placebo	COVID 19 hospitalized	low	163/151	inconclusive	inconclusive 6 % increase in time to recovery (PE) with a high degree of certainty due to low risk of bias
Balcells, 2020 NCT04375098		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	low	28/30	inconclusive	inconclusive 33 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
ConPlas-19, 2020 NCT04345523		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	38/43	inconclusive
Entrenas (Pilot Calcifediol), 2020 NCT04366908		RCT	Vitamin D	standard of care	COVID 19 hospitalized	some concern	50/26	conclusif	inconclusive 88 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias demonstrated 97 % decrease in ICU admission (PE) with a moderate degree of certainty due to some concern in risk of bias
Gharbharan et al., 2020 NCT04342182		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	43/43	inconclusive	inconclusive 5 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
SOLIDARITY (interferon), 2020 NCT04315948		RCT	interferon	control	COVID 19 hospitalized	some concern	2063/2064	inconclusive	inconclusive 16 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
Synairgen SG016, 2020 NCT04385095		RCT	SNG001 inhaled interferon beta	placebo	COVID 19 hospitalized	high	50/51	suggested	suggested 1.3-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias
Abolghasemi, 2020 IRCT20200325046860N1		OBS	convalescent plasma treatment	control	COVID 19 hospitalized	critical	115/74	inconclusive
Annweiler (GERIA-COVID; regular intake of bolus vitamin D), 2020		OBS	Vitamin D	control	COVID 19 hospitalized	NA	29/32	suggested	suggested 93 % decrease in deaths (PE) suggested 92 % decrease in death or ventilation
Annweiler (GERIA-COVID; Vitamin D Supplementation After COVID-19 Diagnosis), 2020		OBS	Vitamin D	control	COVID 19 hospitalized	NA	16/32	inconclusive
COVID 19 all comers meta-analysis
Cai -FAVIPIRAVIR, 2020 ChiCTR2000029600		NRa	interferon	lopinavir/ritonavir	COVID 19 all comers	NA	35/45	suggested	suggested 5.5-fold increase in clinical improvement,clinical improvement (14-day)
Cai -FAVIPIRAVIR, 2020 ChiCTR2000029600		NRa	interferon	interferon	COVID 19 all comers	NA	35/45	suggested	suggested 5.5-fold increase in clinical improvement,clinical improvement (14-day)
COVID-19 mild to moderate meta-analysis
Fu, 2020 ChiCTR2000030262		RCT	interferon / TFF2	standard of care	COVID-19 mild to moderate	some concern	40/40	no results
Idelsis, 2020 RPCEC00000307		RCT	interferon	interferon	COVID-19 mild to moderate	high	30/33	conclusif	demonstrated 2.3-fold increase in PCR-negative conversion (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
Khamis, 2020		RCT	interferon	standard of care	COVID-19 mild to moderate	some concern	44/45	inconclusive
Libster, 2020 NCT04479163		RCT	convalescent plasma treatment	placebo	COVID-19 mild to moderate	low	80/80	conclusif	demonstrated 48 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
PLACID, 2020 CTRI/2020/04/024775		RCT	convalescent plasma treatment	standard of care	COVID-19 mild to moderate	high	235/229	suggested	inconclusive 7 % increase in death or transfer to ICU (PE) but with a low degree of certainty due to high risk of bias suggested 20 % increase in PCR-negative conversion (7-day) but with a low degree of certainty due to high risk of bias
Rastogi, 2020 NCT04459247		RCT	Vitamin D	placebo	COVID-19 mild to moderate	NA	16/24	suggested	suggested 5.3-fold increase in PCR-negative conversion (PE)
Espitia-Hernandez, 2020		NRa	Vitamin D	standard of care	COVID 19 outpatients, COVID-19 mild to moderate	NA	28/7	suggested	suggested 714.0-fold increase in PCR-negative conversion
COVID-19 severe or critically meta-analysis
AlQahtani, 2020 NCT04356534		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	20/20	inconclusive	inconclusive 33 % decrease in ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
Bajpai M, 2020 NCT04346446		RCT	convalescent plasma treatment	control	COVID-19 severe or critically	high	14/15	inconclusive	inconclusive 74 % decrease in off oxygenation (PE) but with a low degree of certainty due to high risk of bias
Davoudi-Monfared, 2020 IRCT20100228003449N2		RCT	interferon	standard of care	COVID-19 severe or critically	high	46/46	no results
Murai, 2020 NCT04449718		RCT	Vitamin D	placebo	COVID-19 severe or critically	some concern	120/120	inconclusive
PlasmAr, 2020 NCT04344535		RCT	convalescent plasma treatment	control	COVID-19 severe or critically	low	228/105	inconclusive	inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias
PlasmAr, 2020 NCT04344535		RCT	convalescent plasma treatment	placebo	COVID-19 severe or critically	low	228/105	inconclusive	inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias
Yekaninejad, 2020 IRCT20100228003449N2		RCT	interferon	standard of care	COVID-19 severe or critically	some concern	33/33	conclusif	demonstrated 2.4-fold increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Li, 2015 ChiCTR2000029757		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	52/51	inconclusive	inconclusive 40 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
Duan, 2020		OBS	convalescent plasma treatment	control	COVID-19 severe or critically	critical	10/10	inconclusive
Hegerova, 2020		OBS	convalescent plasma treatment	control	COVID-19 severe or critically	critical	20/20	inconclusive
Rasheed, 2020		OBS	convalescent plasma treatment	control	COVID-19 severe or critically	critical	21/28	inconclusive
Sean, 2020		OBS	convalescent plasma treatment	control	COVID-19 severe or critically	critical	39/156	inconclusive
Joyner, 2020 NCT04338360		NRa	convalescent plasma treatment	convalescent plasma treatment	COVID-19 severe or critically	serious	515/561	inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID 19 all comers meta-analysis

COVID-19 mild to moderate meta-analysis

COVID-19 severe or critically meta-analysis